A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Potential Anti-tumor Effects of SSGJ-705 in Patients With Advanced or Metastatic HER2-expressing Solid Tumors

Receptor, ErbB-2 Clinical Trial

Official title: A Phase I, Multicenter, Open-Label, First-in-Human Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Potential Anti-tumor Effects of SSGJ-705 in Patients With Advanced or Metastatic HER2-expressing Solid Tumors

Status Not yet recruiting

Clinical Trial Summary

The study will consist of two parts: a dose-escalation part (Part 1) and a dose expansion part (Part 2). In both study parts, SSGJ-705 will be administered，the administration duration may be adjusted based on outcomes of previous patients if necessary) followed by safety, PK, PD, potential anti tumor effects and immunogenicity evaluation.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Receptor, ErbB-2

• NCT number: NCT05145179
• Study type: Interventional
• Source: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
• Contact: Lili Zheng, PMD
• Phone: 18511272561
• Email: zhenglili@3sbio.com
• Status: Not yet recruiting
• Phase: Phase 1
• Start date: December 1, 2021
• Completion date: June 1, 2024